Organon Pharma Indonesia Tbk. vs Surya Semesta Internusa Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Surya Semesta Internusa Tbk. trades at Rp1,695 (market cap 8.23T, 25.63M 24h volume). The key difference: Surya Semesta Internusa Tbk. is far larger — about 78.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SSIA | |
|---|---|---|
Market Cap | 104.4B | 8.23T |
Volume | — | 25.63M |
Lot | — | 256.3K |
Turnover | — | 43.66B |
Average Price | — | 1,703.42 |
Value | — | 43.66B |
Indicative Equilibrium Price | — | 1,695 |
Indicative Equilibrium Volume | — | 2.72K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT. Surya Semesta Internusa Tbk (formerly known as PT. Multi Investment Ltd.) was established based on notarial deed No. 37 dated June 15, 1971 of Umi Sutamto, S.H., notary in Jakarta. It is a publicly-listed company engaged in investment in the shares of subsidiaries that develop and manage industrial and real estate, provide construction services, manufacture and market pre-cast and pre-stressed concrete and own hotels.
Read more on SSIA →